April 14, 2021
IN THIS ISSUE / April 14, 2021
Pulsed dye laser versus ablative fractional CO2 laser for hypertrophic scars
DermWorld Insights and Inquiries: LIDA rose the insulin requirement
Do mucocutaneous eruptions correlate with COVID-19 severity?
Pulsed dye laser versus ablative fractional CO2 laser for hypertrophic scars
In this double-blinded, split-scar study, 30 patients with hypertrophic scars greater than three years old were treated with pulsed dye laser to half the scar and fractional CO2 laser to the other half for three months.
Researchers found that both the PDL and ablative fractional CO2 laser were effective in improving the appearance of older hypertrophic scars as assessed by the Vancouver Scar Scale (VSS). The fractional CO2 laser, however, significantly improved the height and pliability of the scars. Upon histopathologic examination, the CO2-treated sides were superior to the PDL-treated sides with decreased collagen bundle thickness and increased elastic fibers.
Read about the latest advances in laser technology and learn how to navigate the research and acquisition process in this month’s DermWorld.
Related content:
OTC scar treatments: What does the evidence say about efficacy – DermWorld Weekly (October 2020)
Practicing cosmetic dermatology during COVID-19 – DermWorld (November 2020)
Nom de plume: Affair Risquée – DermWorld Insights and Inquiries (December 2016)
DermWorld Insights and Inquiries: LIDA rose the insulin requirement
Cutaneous amyloidosis may be primary or secondary. The latter refers to deposition of amyloid within skin tumors, such as seborrheic keratosis and basal cell carcinoma, and is detectable histologically. Primary localized cutaneous amyloidosis (PLCA) is characterized by the deposition of amyloid in the skin without involving any internal organ, including lichen amyloidosis, macular amyloidosis (keratinic amyloid in both types, derived from degenerated keratinocytes), and nodular amyloidosis (AL amyloid, derived from immunoglobulin light chains). Keep reading!
Actinic keratosis clinical guideline published
Actinic keratosis, rough scaly patches that arise on chronically ultraviolet-exposed skin, is one of the most common conditions diagnosed and treated by dermatologists in the United States. This new guideline, published in JAAD, addresses the management of actinic keratosis, providing evidence-based recommendations for treatment. View guideline highlights and access the full guideline.
Do mucocutaneous eruptions correlate with COVID-19 severity?
According to a study published in JAAD, distinct mucocutaneous patterns were identified in hospitalized adults with COVID-19 and may be linked to more severe clinical course. Among 296 adults hospitalized with COVID-19, 11.8% had at least one disease-related eruption, including ulcer (37.1%), purpura (25.7%), necrosis (14.3%), nonspecific erythema (11.4%), morbilliform eruption (11.4%), pernio-like lesions (11.4%), and vesicles (2.9%).
A greater proportion of patients with mucocutaneous findings used mechanical ventilation (61% vs. 30%), used vasopressors (77% vs. 33%), initiated dialysis (31% vs. 9%), had thrombosis (17% vs. 11%), and had in-hospital mortality (34% vs. 12%).
Access Academy resources related to COVID-19 vaccines, including information on getting vaccinated, advising patients about vaccination, becoming a vaccinator, coding for vaccination, and side effects of vaccines, in the Academy's Coronavirus Resource Center.
Have you seen patients with reactions to a COVID-19 vaccine? Report them to the Dermatology COVID-19 Registry.
What do consumers recall from sunscreen labels?
A report recently published in JAMA Dermatology found that listing active ingredients on the front label of sunscreen products may not be as useful for consumers selecting a sunscreen as previously thought. Consumers’ recall of active ingredients was low, and few reported typically looking at the active ingredients.
According to the study results, active ingredients in sunscreen were not reported to be the primary factor influencing consumers’ sunscreen selection. Of the 47 total participants, 13 (28%) stated that sunscreen ingredients influenced their sunscreen selection, but only five (11%) said it was the most important information. Nearly three-quarters of the participants stated that sun protection factor rating was the most important information.
Dive into the FDA’s proposed rule on the over-the-counter sunscreen monograph and what dermatologists might expect in the coming years in DermWorld.
Related content:
